Adc Therapeutics SA

NYSE:ADCT   3:59:59 PM EDT
35.62
-0.12 (-0.34%)
Products

ADC Therapeutics Announces FDA Accepts Biologics License Application And Grants Priority Review For Loncastuximab Tesirine For Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Published: 11/20/2020 12:37 GMT
(ADCT) - Adc Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed Or Refractory Diffuse Large B-cell Lymphoma.
Adc Therapeutics Sa - Prescription Drug User Fee Act Target Action Date of May 21, 2021.